Diagnostics Makes OVA1 Blood Test Nationally Available
With the availability of OVA1, physicians can assess, prior to a planned surgery, the likelihood that a woman’s ovarian mass is malignant in order to direct her to
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
Brian Scanlan, chief business officer of Cambridge Major Laboratories, said: “Chemistry Playbook accelerates drug development from carbon to commercialization by delivering where other competitive, expedited programs fall short: